Navigation Links
MEDRAD Molecular Imaging Earns Top Rank in Innovation
Date:2/13/2009

New technology reduces radiation exposure, eliminates workflow complexity, and enables patient-scheduling flexibility

WARRENDALE, Pa., Feb. 13 /PRNewswire/ -- MEDRAD's Intego(TM) PET Infusion System has been named one of Medical Imaging Magazine's top eight most innovative products of the year. The magazine designated its top eight based on what its readership considers to be the most far-reaching, game changing or otherwise groundbreaking medical devices on the market.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO )

MEDRAD's Intego PET Infusion System automatically measures and delivers patient-specific Fluorodeoxyglucose (FDG) doses on demand. With on-board dosimetry, the system can deliver precise, repeatable FDG doses within +/- 2% of the measured dose. The Intego also minimizes FDG handling and is fully shielded, reducing radiation exposure by more than 20% compared to conventional (syringe-based) FDG delivery methods.

"Intego technology is raising the standard of care in FDG delivery," says Doug Descalzi, Executive Director of MEDRAD's Molecular Imaging business. "Healthcare professionals gain precision, flexibility and control over workflow, which can help any PET practice grow clinically and safely."

More detailed information on MEDRAD's Intego PET Infusion System is available at www.medrad.com/FDGdelivery

About MEDRAD

MEDRAD, Inc., is a worldwide leading provider of medical devices and services that enable and enhance imaging and therapeutic procedures of the human body. For diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. The company also offers products used in vascular intervention. MEDRAD's total 2007 revenues were $525 million. In 2003, MEDRAD received the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is an affiliate of Bayer AG. More company information is available at www.medrad.com.

The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.

Cautionary statement regarding forward-looking statements.

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and MEDRAD's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. MEDRAD, INC. undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.


'/>"/>
SOURCE MEDRAD, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MEDRAD Announces eCoil(TM) for Siemens, Philips 3.0T MR Scanners
2. MEDRAD Plant Named IndustryWeek Magazine Award Finalist
3. MEDRAD Mobile MR Injector Meets Challenges of MR Trailers
4. MEDRAD(R) Revenues Grow 10 Percent in 2007
5. MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery
6. MEDRAD Receives FDA 510(k) Clearance for Wireless MR Infusion System
7. MEDRAD Multi Vendor Service Forms Alliance with Wetsco
8. MEDRAD Builds on Success of P3T Cardiac CT Injection Software
9. MEDRAD Sponsors PET Research with University of Zurich
10. A new molecular zip code, and a new drug target for Huntingtons disease
11. New knock-out gene model provides molecular clues to breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... ... ... Silicon Valley Hair Institute, the leading hair transplant center in the San ... ARTAS® hair transplant system and the younger demographic. As many younger people suffer from ... of hair restoration. , “It can be emotionally difficult for young men and women ...
(Date:9/22/2017)... Viejo, CA (PRWEB) , ... September 22, 2017 , ... ... Angioma Alliance Walk and 5K honoring Olympian, Florence Joyner, still considered the fastest woman ... malformation (CCM). Flo Jo’s daughter, Mary Joyner, will sing the National Anthem. ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... buildings, and Richard Pedranti Architect (RPA), a full-service architecture firm focusing ... partner’s Solsken Line of Model Homes . Independently, Ecocor and RPA have ...
(Date:9/22/2017)... ... September 22, 2017 , ... SABRE ... Smart Scholarship Sweepstakes.,  , Molli C., a graduate student from Sonora, California, who ... and Administration at St. Thomas University in Miami, Florida, was selected from a ...
(Date:9/22/2017)... ... 2017 , ... “Cursed with a Curse: The Truth about ... freedom experienced when breaking free from this misconception. “Cursed with a Curse: The ... Published by Christian Faith Publishing, Lysa M. Harrison’s new book is a powerful ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
(Date:9/7/2017)... 2017  Eli Lilly and Company (NYSE: ... operations to more efficiently focus resources on developing ... Global workforce reductions, including those from a U.S. ... approximately 3,500 positions. With the ... of approximately $500 million that will begin to ...
Breaking Medicine Technology: